INTRODUCTION 1
CRISPR-Cas systems represent RNA-directed immune systems whose programmable 2 nucleases have become powerful technologies for genome editing, gene regulation, imaging, 3 and diagnostics (Barrangou and Doudna, 2016; Komor et al., 2017) . CRISPR technologies 4 derive from an increasing assortment of CRISPR-associated (Cas) single-effector nucleases 5 (Koonin et al., 2017; Mohanraju et al., 2016) . These nucleases include the originally discovered 6 and widely-used Type II Cas9 nucleases that introduce a blunt cut into dsDNA targets 7 (Gasiunas et al., 2012; Jinek et al., 2012) , the more recently discovered Type V Cas12a (or 8 Cpf1) nucleases that introduce a staggered cut into dsDNA targets and degrade ssDNA upon 9 target recognition (Chen et al., 2018; Zetsche et al., 2015) , and the functionally unique Type VI 10 Cas13a (or C2c2) nucleases that cut ssRNA targets and can non-specifically degrade cellular 11
RNAs upon target recognition (Abudayyeh et al., 2016; Shmakov et al., 2015) . Across this 12 diversity, CRISPR-Cas systems share an inherent capacity for multiplexing through their 13 CRISPR arrays. These arrays are composed of alternating conserved "repeats" and targeting 14 "spacers", where some prokaryotes can encode up to a few hundred spacers in a single array 15 that are stable over evolutionary timescales (Jansen et al., 2002) . The transcribed array 16 undergoes processing into multiple guide RNAs (gRNAs) derived from each repeat-spacer pair. 17
Each gRNA directs the Cas nuclease to bind and cleave complementary DNA or RNA targets 18 flanked by a short protospacer-adjacent motif (PAM) or a protospacer-flanking sequence (PFS) 19 (Leenay and Beisel, 2017) . 20
The multiplexing capacity of CRISPR arrays was well recognized before the advent of 21 CRISPR-Cas9 technologies (Barrangou et al., 2007; Brouns et al., 2008) . However, multiplexing 22 with Cas9 outside of bacterial systems was constrained by the limited portability of RNase III 23 and the trans-activating CRISPR RNA (tracrRNA) necessary for processing of Cas9 arrays 24 (Cong et al., 2013) . The invention of the single-guide RNA (sgRNA) obviated the need to co-25 express the tracrRNA and RNase III (Jinek et al., 2012) , although the sgRNA sacrificed the 1 inherent multiplexing capability of CRISPR arrays and therefore required numerous engineering 2 workarounds to produce multiple sgRNAs (Nissim et al., 2014; Wong et al., 2016; Xie et al., 3 2015) . The discovery that the Cas12 and Cas13 nucleases processed CRISPR arrays through 4 their own endonucleolytic domains (East-Seletsky et al., 2016; Fonfara et al., 2016; Zetsche et 5 al., 2015; Zhong et al., 2017) intensified the pursuit of synthetic CRISPR arrays for multiplexing 6 applications. More recent examples include multiplexed genome editing and gene activation 7 with Cas12a (Tak et al., 2017; Zetsche et al., 2016) , and multiplexed gene silencing with 8
Cas13a (Abudayyeh et al., 2017) . Beyond these recent demonstrations, use of arrays could 9 also advance many other CRISPR technologies that have yet to employ CRISPR arrays for 10 multiplexing, such as paired nickases or FokI fusions (Guilinger et al., 2014; Tsai et al., 2014) , 11 enhanced gene drives (Noble et al., 2017) , proximal CRISPR targeting (Chen et al., 2017a) , 12 multi-pathogen antimicrobials (Fagen et al., 2017) , multiplexed base editing (Banno et al., 13 2018), combinatorial nucleic-acid sensing with Cas12a and Cas13a (Chen et al., 2018; 14 Gootenberg et al., 2017) , and combinatorial screens (Billon et al., 2017; Kuscu et al., 2017; 15 Peters et al., 2016) . However, one of the major barriers impeding multiplexing applications is 16 how to generate CRISPR arrays. 17
As a default, CRISPR arrays would be chemically synthesized as linear dsDNA by 18 commercial vendors. Unfortunately, the reoccuring repeat sequences inherent to these arrays 19 currently pose major technical complications when assembling individually synthesized 20 oligonucleotides, resulting in vendors regularly rejecting customer requests even for a minimal 21 single-spacer array. Gene synthesis has offered a more reliable means of obtaining custom 22 CRISPR arrays. However, synthesis often comes at large cost (~5x the price of a linear dsDNA) 23 and timeframes (~1 month), and the synthesis can often fail. As an alternative, a few groups 24 have developed different assembly methods based on annealing shorter oligonucleotides into 25
PcF-2/3/1 and PcF-1/3/2 arrays that negligibly or efficiently cleared the plasmid with the lacZ 23 promoter sequence, respectively (Fig. 2B) . The lacZ promoter-targeting gRNA in PcF-2/3/1 had 24 the lowest abundance across the two arrays and was ~4-fold lower than the same gRNA in 25
PcF-1/3/2 relative to the middle spacer in each array--all in line with poor plasmid clearance 1 activity. We also noticed that the most-abundant gRNAs were derived from the terminal repeat. 2 These gRNAs could be titrating out available FnCas12a protein, resulting in negligible DNA 3 targeting by less-abundant gRNAs. Given that the terminal repeat is not necessary to generate 4 a functional gRNA (Zetsche et al., 2015) , we removed this repeat from both arrays and repeated 5 the plasmid-clearance assay. However, removing the terminal repeat did not appreciably 6 improve plasmid clearance (Fig. S3A) . Therefore, other factors likely account for the context-7 dependent loss of targeting activity. 8
We also explored whether array assembly and multiplexed plasmid clearance could 9 extend to other Cas12a proteins. We chose the Cas12a nuclease from Acidaminococcus sp. 10 BV3L6, one of the most commonly used variants of Cas12a (Tang et al., 2017; Zetsche et al., 11 2015) . As expected, we were able to readily generate three-spacer arrays and achieve 12 multiplexed plasmid clearance. All three spacers led to robust plasmid clearance whether in 13 one-spacer arrays or in a three-spacer array (Fig. S3B) FnCas12a, where single point mutations completely (D917A, E1006A) or partially (D1255A) 20 disrupted DNA cleavage activity while retaining DNA binding activity in vitro (Fonfara et al., 21 2016; Zetsche et al., 2015) . Single or double point mutations of these domains have been used 22 for programmable gene regulation with Cas12a in bacteria, mammalian cells, and plants 23 (Leenay et al., 2016; Tak et al., 2017; Tang et al., 2017) , yet the mutations remain to be 24 compared systematically. We therefore generated variants of Cas12a containing single, double, 25 or triple mutations and then measured DNA targeting of each catalytically-dead variant of 1 FnCas12a (dFnCas12a) based on plasmid clearance or gene repression in E. coli (Fig. 3A) . For 2 either assay, each variant was co-expressed with a single-spacer array targeting the lacZ 3 promoter controlling gfp on a transformed plasmid. The transformations were performed in an E. 4 coli strain lacking this promoter to prevent incidental genome targeting. We found that all tested 5 mutations eliminated any measurable plasmid clearance activity and yielded GFP repression by 6 flow cytometry analysis. Interestingly, one of the single mutations (E1006A) exhibited greatly 7 reduced repression activity that was reversed with additional mutations. Aside from the E1006A 8 single mutation, all other mutations yielded similar strengths of gene repression. 9
We selected the triple mutant (D917A, E1006A, D1255A) to evaluate multiplexed gene 10 repression in E. coli. We designed spacers to target the lacZ, lacIq, or araB promoter controlling 11 gfp in separate plasmids. We then constructed single-spacer or three-spacer arrays and 12 performed flow cytometry analysis to determine the extent of gene repression for each 13 combination of promoter-arrays in comparison to the no-spacer array (Fig. 3B) . As expected, 14 each single-spacer array silenced GFP expression only from the cognate promoter, whereas all 15 three-spacer arrays that we tested silenced GFP for all promoters. We also observed some 16 variability in GFP silencing between the tested three-spacer arrays, suggesting some impact of 17 the spacer context, although there was no complete loss of silencing activity. 18
One of the promising uses of Cas12a is multiplexed gene activation in eukaryotic cells, 19 yet only one study has demonstrated this capability to-date (Tak et al., 2017) . We therefore 20 sought to evaluate gene activation in the budding yeast Saccharomyces cerevisiae using a 21 fusion between the FnCas12a double mutant (D917A, E1006A) and the transcriptional activator 22 domain VP64. For these experiments, we constructed a new base CRISPR plasmid with the 23 SNR52 snoRNA promoter and a polyT terminator. We then constructed single-spacer or three-24 spacer arrays targeting different locations around the CYC1 promoter, which drives expression 25 of a downstream chromosomal copy of yeGFP. Flow cytometry analysis showed that each 1 single-spacer array yielded up to 6.6% yEGFP-expressing cells, while the three-spacer arrays 2 consistently yielded 11% yEGFP-expressing cells (Figs. 3C, S4) . Furthermore, the average 3 fluorescence values were higher for cells with the three-spacer arrays than any of the single-4 spacer arrays (Fig. S4) , mirroring the synergistic impact of recruiting multiple activators to the 5 same promoter as observed for dCas9 (Maeder et al., 2013; Perez-Pinera et al., 2013) . The 6 observed activation of yEGFP expression was lost when using dFnCas12a without the fused 7 transcriptional activator domain (Fig. S4) . In total, we showed that CRATES can be used to 8 generate Cas12a arrays for multiplexed gene repression in E. coli and multiplexed gene 9 activation in yeast, creating the potential of implementing these arrays in different eukaryotic 10 organisms. 11 12 CRATES is compatible with other Class 2 CRISPR nucleases. We have so far shown that 13 CRATES can be used to construct CRISPR arrays utilized by Cas12a. However, the basis of 14 the assembly method--junctions in the trimmed portion of the spacers--is not limited to Cas12a 15 arrays. Instead, all other Class 2 CRISPR-Cas systems that have been characterized to-date 16 exhibit spacer trimming (Deltcheva et al., 2011; East-Seletsky et al., 2016; Shmakov et al., 17 2015) . This common feature would suggest that CRATES could be compatible with any Class 2 18 CRISPR nuclease. As a start, we adapted CRATES to assemble CRISPR arrays recognized by 19 the Type II-A single-effector nuclease Cas9 from Streptococcus pyogenes (SpCas9), arguably 20 the most widely used CRISPR nuclease to-date (Fig. 4A) . The major alteration to the base 21 plasmid was placing the repeat upstream of the 5' restriction site so the assembly junction 22 would fall within 5' trimmed region of each spacer. Co-expressing the resulting arrays, Cas9, 23 and the tracrRNA in a bacterium with RNase III would lead to processing of the CRISPR array 24 into individual gRNAs (Deltcheva et al., 2011) . To demonstrate this functionality, we designed 25 spacers targeting three plasmids respectively. We then cloned three single-spacer arrays and 1 one three-spacer array and performed the plasmid clearance assays in E. coli. As expected, the 2 single-spacer arrays only cleared their cognate target plasmid, while the three-spacer assay 3 cleared all three plasmids. 4
As a further demonstration, we used CRATES to explore multiplexed RNA sensing with 5 the Type VI single-effector nuclease Cas13a from Leptotrichia shahii (LsCas13a). This nuclease 6 possesses the unique ability to target RNA, where target recognition activates a separate 7 endonuclease domain within LsCas13a that non-specifically degrades cellular RNAs 8 (Abudayyeh et al., 2016) . The non-specific activity was recently exploited for the sensitive 9 detection of viral RNAs (Gootenberg et al., 2017 (Gootenberg et al., , 2018 , while this same activity was sufficiently 10 low in human cells to allow programmable and targeted gene silencing with the wild-type 11 nuclease (Abudayyeh et al., 2017) . Because the LsCas13a spacer is trimmed on the 3' end as 12 part of gRNA processing (East-Seletsky et al., 2016; Shmakov et al., 2015) , we developed a 13 base assembly construct similar to that for Cas12a (Fig. 4C) . We then devised an RNA-sensing 14 assay using TXTL, where DNA encoding LsCas13a and the constructed CRISPR array were 15 mixed with DNA expressing a target RNA and a non-targeted GFP reporter (Fig. S5A,B) . The 16 GFP transcript would undergo non-specific degradation only when the processed gRNA is 17 paired with its target, resulting in a reduction of GFP fluorescence. We created three unique 18 spacers and three complementary targets placed downstream of a constitutive promoter. As 19 expected, GFP expression was reduced compared to the no-spacer array only when the gRNA 20 and its target were both present. Furthermore, the three-spacer arrays reduced GFP in the 21 presence of any of the three target transcripts but not of a non-targeted transcript, resulting in 22 the simultaneous sensing of multiple RNA species (Figs. 4D, S5C) . Interestingly, some 23 transcripts led to more potent GFP silencing than others, presumably due to ranging secondary 24 structures impacting the accessibility of the target sequence as reported previously (Abudayyeh 1 et al., 2016) . wide screen (Najm et al., 2018) . However, in each case, the gRNAs had to be transcribed from 9 separate expression constructs. We therefore asked if CRATES could be used to generate 10 CRISPR arrays that are processed into gRNAs recognized by multiple Cas nucleases--in what 11
we term "composite" arrays. The simplest arrangement for a composite array would be multiple 12 CRISPR arrays inserted sequentially into the same transcript. Figure 5A illustrates a composite 13 array composed of a two-spacer SpCas9 array followed by a two-spacer FnCas12a array (Fig.  14 
5B). 15
To explore the technological potential of composite arrays, we first assessed the ability 16 of these arrays to coordinate plasmid clearance by SpCas9 and gene repression by the 17 FnCas12a triple mutant (D917A, E1006A, D1255A) in E. coli (Fig. 5C ). As part of the 18 assessment, we designed two spacers for each nuclease targeting the lacZ or lacIq promoter 19 controlling gfp in the reporter plasmid. We then constructed arrays containing each spacer or all 20 four spacers in two configurations (Fig. 5C ). E. coli cells harboring the SpCas9 or FnCas12a 21 triple-mutant plasmid and either GFP reporter plasmid were transformed with each CRISPR 22 plasmid. We then assessed the transformation efficiency (SpCas9) or GFP fluorescence 23 (dFnCas12a) in comparison to a no-spacer array. As expected, the single spacers yielded 24 plasmid clearance or GFP repression when matched with their nuclease and targeted plasmid, 25 while one of the four-spacer composite arrays (Pc7/8/9/10) yielded plasmid clearance or GFP 1 repression comparable to that of all single-spacer arrays. Interestingly, the other four-spacer 2 composite array with swapped SpCas9 spacers (Pc8/7/9/10) exhibited greatly reduced plasmid 3 clearance of one target plasmid by SpCas9, paralleling the diminished activity of one of the 4 FnCas12a spacers used for plasmid clearance ( Fig. 2A) . 5
6
Composite arrays can improve on-target specificity through coordinated blocking of off-7 target sites. Following the proof-of-principle demonstration of composite arrays, we sought a 8 more practical application that benefits from coordinated DNA binding and cleavage. One 9 unexplored application is reducing off-target activity by using a catalytically-dead nuclease to 10 bind--and therefore block--known off-target sites. This strategy could be used in combination 11 with existing approaches for diminishing off-target editing such as modified gRNAs or improved-12 specificity variants of Cas9 (Chen et al., 2017b; Fu et al., 2014; Hu et al., 2018; Kleinstiver et al., 13 2016a; Slaymaker et al., 2016; Yin et al., 2018) , and it could directly exploit a growing suite of 14 experimental techniques for the unbiased detection of off-target sites (Tsai and Keith Joung, 15 2016). Most importantly, it could allow the selection of target sites that otherwise might have 16 been rejected because of known off-target locations. 17
We chose SpyCas9 for on-target cleavage and the FnCas12a triple mutant to block off-18 target sites (Fig. 5C) . We further selected one of the first examples of off-target cleavage by 19 SpCas9 in human cells: an on-target site in WAS CR-4 (P-on), and two off-target sites in STK25 20 (P-off1) and GNHR2 (P-off2) ( Fig. S6A) (Fu et al., 2013) . The target sites for FnCas12a were 21 chosen so the R-loop would extend through the NGG PAM recognized by SpCas9, thereby 22 presumably preventing any DNA recognition. 23
We used TXTL as a rapid and dynamic means to assess whether the catalytically-dead 24
FnCas12a could block SpCas9-mediated cleavage of the off-target sites but not the on-target 25 site. As part of the assay, the target sites were inserted ~170 bps upstream of the P70a 1 promoter controlling gfp. Cleavage by SpCas9 would result in rapid degradation by RecBCD 2 and loss of GFP production ( Fig. S6B) (Maxwell et al., 2018) . Using CRATES, we assembled a 3 variant of the composite array encoding the targeting SpCas9 sgRNA upstream of a two-spacer 4
FnCas12a array, where both configurations of the FnCas12a spacers (Psg/b1/b2 and 5
Psg/b2/b1) were tested. We then assayed the cleavage activity of SpCas9 on each site by first 6 adding to the TXTL reaction the FnCas12a triple-mutant plasmid, a reporter plasmid, and either 7 the plasmid encoding a composite array or two plasmids separately encoding the sgRNA and a 8 single-spacer FnCas12a array. We then added the plasmid encoding SpCas9 and measured 9 GFP fluorescence over time. The protection efficiency was then calculated based on the rate of 10 GFP production in comparison to that when expressing a no-spacer FnCas12a array and the 11 targeting sgRNA (0% protection) or a non-targeting sgRNA (100% protection). We found that 12 both tested composite arrays inhibited cleavage by SpCas9 at both off-target sites at 13 efficiencies similar to those when expressing the SpCas9 sgRNA and single-spacer FnCas12a 14 arrays separately (Fig. 5E) . Critically, there was negligible protection for the on-target site. 15
These results therefore offer an proof-of-principle demonstration of using composite arrays to 16 improve on-target specificity by Cas nucleases. 17
18

DISCUSSION 19
We have devised and validated a technique we term CRATES for the efficient, one-step 20 generation of large CRISPR arrays. The technique relies on assembling multiple repeat-spacer 21 subunits using defined junction sequences within the trimmed portion of the CRISPR spacers. 22
By specifying the sequence and 5' or 3' directionality of the overhang that forms the junction, we 23 could minimize unintended pairing between non-adjacent repeat-spacer subunits. We showed 24 that the technique could generate CRISPR arrays harboring up to seven spacers with high 25 efficiency. While the technique may extend to even larger arrays, the cloning efficiency could be 1 further improved by using different junction lengths (e.g. between 1 and 10 nts for Cas9 2 spacers) and by subjecting the repeat-spacer oligonucleotides to further purification to remove 3 truncated products. 4
We showed that the assembled arrays could be utilized by three different single-effector 5 nucleases (Cas9, Cas12a, Cas13a) that yielded multiplexed DNA or RNA targeting in bacteria, 6
eukaryotic cells, and cell-free systems. Given the numerous applications for CRISPR 7 technologies that could benefit from multiplexing--from genome editing, epigenetic regulation, 8
and gene drives to nucleic-acid sensing, antimicrobials, and genetic screens--CRATES has the 9 potential to be widely implemented. Two particularly noteworthy uses are for gene drives and 10 genetic screens. Gene drives utilize a CRISPR nuclease transferring itself and any adjacent 11 genetic cargo to the matching locus in a sister chromosome, thereby allowing the rapid spread 12 of the cargo through a wild population (Esvelt et al., 2014) . Because this technique relies on 13 homologous recombination, indel formation through non-homologous end joining (NHEJ) would 14 prevent further editing and create a drive-immune member of the population. By targeting 15 multiple sites in the matching locus through a generated array, disruption of the gene drive 16 through indel formation could be greatly reduced or even eliminated due to the vanishingly small 17 probability that all sites undergo repair through NHEJ simultaneously. In the second example, 18 CRISPR technologies have been used for genome-wide screens based on gene disruption, 19 activation, or repression (Shalem et al., 2015) . While these screens principally relied on a library 20 of single sgRNAs, there are recent examples where libraries containing sgRNA pairs were used 21 in human cells to identify synthetic-lethal genes as well as gene pairs that drive cancer 22 proliferation or interact with tumor protein p53 (Najm et al., 2018; Wong et al., 2016) . In both 23 examples, the sgRNAs had to be cloned sequentially. CRATES therefore could build on these 24 approaches through the one-step assembly of array libraries that extend beyond two targets, 25 allowing the combinatorial screening of large and potentially redundant factors such as virulence 1 factors, small RNAs, or two-component systems. 2
We also assembled composite arrays that could be utilized by multiple nucleases (Fig.  3   5) . These arrays created the opportunity to enact multiple multiplexed functions by CRISPR 4 nucleases from a single transcript. While expressing or delivering more than one nuclease can 5 be cumbersome, there have been a few applications that benefited from multiple nucleases. In 6 one example, the frequency of gene editing was enhanced by directing catalytically-dead 7
SpCas9 to bind proximally to the site targeted by an orthogonal and catalytically active Cas9 or 8
Cas12a (Chen et al., 2017a) . In another example cited above, the SpCas9 and Staphylococcus 9 aureus (Sa)Cas9 were used to perform combinatorial screens, where SpCas9 created indels 10 while SaCas9 upregulated gene expression (Najm et al., 2018) . In both examples, composite 11 arrays could be used to expand the number of targeting gRNAs produced at one time--whether 12 to enhance editing at one or multiple sites or to increase the number of target genes in a 13 combinatorial screen. We also reported another use of composite arrays based on blocking 14 known off-target sites (Fig. 5D) . While this approach remains to be demonstrated in cells, it 15 suggests another means to reduce off-target effects that would complement existing strategies 16 and resurrect the use of targets with known off-target sites. This feature would be especially 17 important for edits that can only be achieved through a limited number of target sites, such as 18 for reversing single-nucleotide polymorphisms associated with human disease or performing 19 site-specific integrations (Bulik-Sullivan et al., 2015; Eyquem et al., 2017) . 20
Our assembly scheme depended on the insertion of junctions into the trimmed portions 21 of spacers within a CRISPR array. To-date, spacer trimming has been associated with all Class 22 2 CRISPR-Cas systems (II, V, VI) and with some Class 1 Type III CRISPR-Cas systems (Hale 23 et al., 2009 ). On the other hand, Type I CRISPR-Cas systems have not been reported to 24 undergo spacer trimming because of the mechanism of ribonucleoprotein complex assembly 25 (Brouns et al., 2008) and because at least one system has been shown to reject mismatches at 1 the PAM-distal end of the spacer (Szczelkun et al., 2014) . CRATES could generate CRISPR 2 arrays for Type I systems by using part of the natural spacer sequence as the junction, where 3 the use of 5' or 3' overhangs could be optimized to help eliminate potential cross-interactions 4 between non-adjacent repeat-spacer subunits. This potential limitation aside, Class 2 CRISPR-5
Cas systems and their single-effector nucleases remain the primary source of CRISPR 6 technologies and would benefit directly from CRATES. 7
By testing a large cohort of assembled CRISPR arrays, we observed two unique 8 features that could impact their technological potential. One unique feature was spacers being 9 inactive in multi-spacer arrays despite being fully active in single-spacer arrays. In particular, we 10 found an FnCas12a spacer and an SpCas9 spacer that lost their ability to elicit targeted plasmid 11 clearance in the respective context of a three-spacer array ( Fig. 2A) or a four-spacer composite 12 array (Fig. 5C) . The effect could not be solely explained by the location of the spacer, as 13 swapping the order of the other spacers restored activity. Instead, the lost activity appears to be 14 context-dependent and could involve interactions with adjacent spacers such as through 15 secondary structure formation. While the lost activity was sparingly observed in our work 16 (individual spacers in 2/26 tested arrays) and was not observed in the few instances in which 17 individual spacers in synthetic arrays were assayed (Luo et al., 2016; Zetsche et al., 2016) , it 18 nonetheless could represent an important issue particularly for arrays that cannot be fully 19 validated before they are implemented (e.g. combinatorial screens, editing in multicellular 20 organisms). 21
Although the exact mechanism underlying the loss of spacer activity remains unclear, we 22 provided evidence linking spacer activity to the low abundance of the resulting gRNA (Fig. 2B) . 23
Interestingly, natural CRISPR arrays exhibit widely varying abundances of the processed 24 gRNAs that is only partially explained by the proximity to the transcriptional start site (Carte et 25 al., 2014; Deltcheva et al., 2011; Plagens et al., 2014; Zetsche et al., 2015) . Instead, gRNA 1 abundance varied widely and was not limited to any single type of CRISPR-Cas system, 2 suggesting that this is a common phenomenon impacting the processing of natural and 3 synthetic gRNAs. More experiments will be necessary to determine why some gRNAs are lower 4 in abundance than others, the connection between abundance and activity, and whether design 5 rules can be elucidated to ensure consistent and high gRNA abundance even for large CRISPR 6 arrays. 7
The second unique feature that we observed was FnCas12a deriving a gRNA from the 8 terminal repeat in a CRISPR array. This observation was unexpected given that only spacers 9 flanked by two repeats would be expected to become gRNAs. The more concerning ramification 10 is that the terminal repeat-derived gRNA could lead to unintended targeting. From a natural 11 perspective, we provided evidence that terminal repeats for Cas12a arrays have been under 12 negative selection to prevent formation of a gRNA, resulting in mutations within the terminal 13 repeat that disrupt processing. Correspondingly, the one native Cas12a array subjected to RNA-14 seq analysis--from FnCas12a--did not show any gRNAs derived from the terminal repeat 15 (Zetsche et al., 2015) . From a technological perspective, Cas12a gRNAs can be functionally 16 expressed without a 3' repeat (Kleinstiver et al., 2016b; Zetsche et al., 2015) ; however, the 17 terminal repeat was important when deriving gRNAs from eukaryotic mRNAs ( Maxwell, C.S., Jacobsen, T., Marshall, R., Noireaux, V., and Beisel, C.L. (2018) . A detailed cell-7 free transcription-translation-based assay to decipher CRISPR protospacer-adjacent motifs. 8
Methods (in press). 9
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METHOD DETAILS 6
Strains, Plasmids, and Growth Conditions. All strains, plasmids, and oligonucleotides are 7 listed in Table S2 and Table S3 . For experiments in E. coli and TXTL, SpCas9 was expressed 8 from pCas9 (Addgene #42876) while the other cas genes were expressed under the control of 9 the J23108 promoter in a pBAD33 backbone. The targeted plasmids used with the plasmid 10 clearance assays for FnCas12a were constructed by Q5 mutagenesis (New England Biolabs) 11 following the manufacturer's instructions to remove portions of the pUA66-lacZ plasmid (GFP 12 gene driven by lacZ promoter) so that each targeted plasmid only contain one protospacer 13 matching to the designed spacers. The targeted plasmids used with the plasmid clearance 14 assays for SpCas9 were constructed by inserting the fragments containing the PAM and 15 protospacer in between the XhoI and BamHI sites of pUA66. The GFP reporter plasmids used 16 with the gene repression assays were constructed by inserting a constitutive (lacIQ) or inducible 17 promoter (lacZ or araB) into the XhoI and BamHI restriction sites upstream of the gfp gene in 18 pUA66 (Zaslaver et al., 2006) . The reporter plasmid for in vitro RNA detection with LsCas13a 1 was the p70a-deGFP plasmid reported previously (Garamella et al., 2016) . The target encoding 2 plasmids were constructed by inserting the protospacer into the plasmid pUA66_PJ23119 by 3 replacing the ORF of GFP gene. Plasmid p70a-deGFP was also used for the off-target binding 4 experiments by inserting each target sequence to upstream of the P70a promoter using Q5 5 mutagenesis . The Cas12a encoding plasmids were constructed by inserting the open reading 6 frame of FnCpf1 or AsCpf1 into pBAD33 with a constitutive promoter (PJ23108). The plasmids 7 encoding dFnCas12a variants were constructed by Q5 mutagenesis using the wild type 8
FnCas12a plasmid as template. Plasmid used for expressing Cas9 was pCas9 (Addgene # 9 42876). Plasmid pCas9-notracr was constructed by removing the tracrRNA portion from the 10 plasmid pCas9 using Q5 mutagenesis. The in vivo plasmid clearance assays were conducted in 11 CB414, a derivative of E. coli BW25113 with the lacI promoter through the lacZ gene and the 12 endogenous I-E CRISPR-Cas system deleted. The S. cerevisiae strain YPH500 (Stratagene) was used as the background strain for 19 gene activation. Culturing and genetic transformation were done as previously described (Khalil 20 et al., 2012) using either URA3, HIS3, or LEU2 as selectable markers. The reporter plasmid for 21 gene activation was constructed from integrative plasmid pRS406 (Strata-gene) as described 22 previously (Keung et al., 2014) . A CEN pRS414 plasmid was used to express the FnCas12a 23 variants from a GPD promoter. To construct FnCas12a-VP64, the FnCas12a double mutant 24 was cloned in between pGPD and VP64 in pRS414 through Gibson assembly. All plasmid 25 constructs were generated using TOP10, Novablue, Tg1, or DH5α electrocompetent cells and 1 verified by PCR and Sanger Sequencing of the inserted sequence. 2 3 Generation of CRISPR arrays. The backbone plasmid used for generating CRISPR arrays for 4 FnCas12a (pFnCpf1GG) was constructed by Gibson assembly to join three PCR fragments 5 together and kill the extra BsmBI site on the scaffold backbone. The three PCR fragments 6 contain a constitutive J23119 promoter, a GFP dropout construct (with promoter and terminator) 7 flanked by two Type IIS BsmBI restriction sites and a direct repeat of FnCas12a, and rrnB 8 terminator, ampicillin resistance gene, and pMB1 origin of replication, respectively. The 9 backbone plasmid used for generating arrays for AsCas12a, and LsCas13a, and the 4-spacer 10 composite arrays were constructed using Q5 mutagenesis to remove the FnCas12a repeat and 11 insert the other corresponding repeats. The backbone plasmid used for generating arrays for 12 SpCas9 was constructed by inserting a PCR fragment with the Cas9 direct repeat and BsmBI 13 sites flanked mRFP dropout construct into AatII and HindIII digested pFnCpf1GG. Backbone 14 plasmid for generating composite arrays for blocking off-target cleavage was constructed using 15 Q5 mutagenesis to remove extra nucleotides on the 3' of the promoter from pFnCpf1GG, so that 16 the transcription starts from the sgRNA of Cas9. Backbone plasmid for generating arrays to use 17 in yeast was constructed by using Gibson Assembly to join three PCR fragments and mutate a 18
BsaI site on the scaffold backbone: BsaI sites flanked GFP dropout construct and two PCR 19 fragments amplified from plasmid pRS413, on which arrays are transcribed from a SNR52 20 snoRNA promoter. The sequences of the resulting backbone plasmids are available in Table  21 S2. Forward and reverse oligonucleotides encoding one repeat, one spacer, and a 4-nt junction 22 were annealed to form dsDNA with a 5' and/or 3' overhangs. 400 fmol of each dsDNA, 20 fmol 23 of backbone plasmid, 1 µl of T7 ligase, and 1 µl of BsmBI or BsaI were added to 2 µl of T4 24 ligation buffer, then water was added to reach a total volume of 20 µl. A thermocycler was used 25 to perform 25 cycles of digestion and ligation (42 °C for 2 min, 16°C for 5 min) followed by a 1 final digestion step (60°C for 10 min), and a heat inactivation step (80°C for 10 min). The ligation 2 mix was then diluted 1:6 in water and electroporated into competent E. coli cells. After 3 transformation and recovery for 1 hour at 37°C with shaking at 250 rpm in SOC media, cells 4 were plated on LB agar containing the appropriate antibiotic and incubated for 16 h. White 5 colonies were then screened for the presence of the correct band size, and the array was 6 validated through Sanger sequencing of the PCR product. See Methods S1 for a detailed 7 protocol and an example of assembling one of the three-spacer FnCas12a arrays. 8
The no-spacer control used in most of the experiments was generated by inserting a 9 single repeat into the backbone plasmid, resulting in two consecutive repeats with no 10 intervening spacer. 11
Composite arrays for coordinated plasmid clearance and gene repression were 12 generated using the same method except that the backbone plasmid had a 5' direct repeat for 13 starting from separate colonies. All arrays were assembled using the junctions specified in 7 Table S3 . Related to Figure S4 and Tables S2-S3 LsCas13a plasmid, the indicated array plasmid, a plasmid expressing one of the targets, and 6 the GFP plasmid. Target recognition leads to non-specific degradation of the GFP mRNA by 7 LsCas13a, thereby reducing GFP production. End-point fluorescence measurements are 8
reported. Values represent the average of three TXTL experiments and are representative of at 9 least three experiments conducted on different days. All arrays were assembled using the 10 junctions specified in Table S3 . See Figure S5 for the assay and GFP timeccourses. Related to 11 Figure S5 and Tables S2-S3 . were transformed with a plasmid encoding the indicated CRISPR array or a no-spacer array. To 9 investigate the GFP repression, cells harboring the dFnCas12a (D917A, E1006A, D1255A) 10 plasmid, a target plasmid, and a plasmid encoding the indicated CRISPR array or a no-spacer 11
